Antisense Drug Targeting c-myb Oncogene Starts Phase 1 Trial in Patients with Advanced Cancer
New Genta Pipeline Drug Targets Master Regulatory Gene for Cancer Cell Growth
G4460 is part of Genta's DNA/RNA Medicines program. G4460 targets an oncogene product known as c-myb, which is a protein that directly binds to cellular DNA. C-myb is believed to regulate the expression of other genes that are involved in the growth and differentiation of cancer cells. Over-expression of c-myb blocks differentiation, promotes proliferation, and decreases apoptosis. Potential clinical targets for G4460 include CML, melanoma, neuroblastoma, and cancers of the breast, pancreas and colon. Genta has licensed key patents and technology related to the composition and human use of G4460.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.